Skip to content
B16-F10 Mouse Model
The B16F10 murine model of melanoma is widely used in immuno-oncology, as this model enables preclinical evaluation of tumor growth, metastasis, and novel cancer therapeutics. The need for new and effective treatments is urgently growing as incident levels of melanoma, the deadliest form of skin cancer, have significantly increased over the last decade.
We have characterized the B16F10 mouse model of melanoma implanted subcutaneously as a flank model in C57BL/6 mice. This model can also be implanted orthotopically (intradermal) or intravenously to study lung metastases.
Fast Growing and Reproducible
Our B16F10 syngenetic mouse model tumors reflects late-stage tumorigenesis with mean tumor burden reaching euthanasia criteria within a month of inoculation allowing for efficient analysis of novel therapeutic agents.
Fully Characterized Model
This model can be used in an orthotopic (flank) application to study spontaneous metastases or injected intravenously to study lung metastases.
B16F10 Murine Melanoma
The B16F10 murine melanoma cell line was developed from the tenth passage of a B16 melanoma isolated from a C57BL/6 mouse.
BRAF V600E, KIT and TERT promoter mutations are absent within the B16F10 cell line.
The B16F10 cell line often shows resistance to conventional chemotherapy agents and can develop resistance to targeted therapies that aim at specific signaling pathways such as BRAF inhibitors.
The B16F10 line is characterized by NRAS (neuroblastoma RAS viral oncogene homolog), PTEN (phosphatase and tensin homolog), and p53 mutations. Other mutations occur among MAPK and PI3K/AKT pathway activation.
Highly or Overexpressed: MART-1, Tyrosinase, and gp100 (pmel17) (melanoma- specific markers), CD44, αvβ3, and αvβ1 (cell surface markers), MMPs and C-MYC
Downregulated or Not Expressed: p53 and INK4a/ARF (tumor suppressor markers), DOPA and MC1R (differentiational markers), MHC Class I (immune marker), E-Cadherin, β-catenin
(Melnikova et al. 2004)
Although B16F10 tumors may be resistant to some chemotherapies, some commonly used ones include doxorubicin, cisplatin, and temozolomide. Other treatments include immunotherapies such as Anti-PD-1 and Anti-CTLA-4.
Commonly Requested Endpoints
Histopathology
Our customizable histopathological analysis can help evaluate tumor microenvironments, track tumor progression and metastases and inform treatment decisions.
Flow Cytometry
Our flow cytometry expertise can help characterize tumor-infiltration T lymphocytes, identity immune biomarkers, and so much more.